Immedica AB
https://immedica.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Immedica AB
EMA Backs Approval Of Santhera’s Agamree, Pfizer’s Elrexfio & Several Other New Drugs
Four new orphan medicines were among the products recommended for pan-EU marketing approval by the European Medicines Agency this week.
Santhera’s Vamorolone For DMD Among Orphan Drugs Up For EU Marketing Decision
The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing authorization for a number of new products.
Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
Company Information
- Industry
- Distributors
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Impilo AB, Medical Need Europe AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice